A Study of Ruxolitinib in Patients With Graft-Versus Host Disease | stella

Learn Data Labs For Researchers Find trials matched to me

Learn Data Labs For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Ruxolitinib in Patients With Graft-Versus Host Disease | stella

Back to Graft-Versus-Host Disease trials

Recruiting

Plain-English translation of NCT07594587 on ClinicalTrials.gov ↗ · Source last updated June 2026 · How we translate trials

Trial locations(1 site)

Japan

Novartis, Tokyo

Key details

Sponsor

Novartis Pharmaceuticals

Enrollment target

~395 participants

Started

May 2026

Primary completion

May 2030

Age range

0 Years and older

Last updated on clinicaltrials.gov in June 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Novartis Pharmaceuticals

Novartis Pharmaceuticals

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov

Follow this trial

Get notified in plain English when this trial's status changes. No account required.